144
16
1
8
1
Cat. No. | Product Name | ||
---|---|---|---|
L2193 | 抗肝癌化合物库 | 1787 compounds | |
1787 种与肝癌相关的化合物,可以用于抗肝癌药物研发和药理研究; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5466 |
Tyrosine kinase-IN-1
|
VEGFR; FGFR; FLT; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Tyrosine kinase-IN-1是一种多靶点酪氨酸激酶抑制剂,能够抑制KDR (IC50:4 nM),Flt-1 (IC50:20 nM),FGFR1 (IC50:4 nM) 和 PDGFRα (IC50:2 nM)。 | |||
T6996 |
SU 5402
SU5402 |
VEGFR; FGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SU 5402 是多靶点受体酪氨酸激酶抑制剂,能够抑制VEGFR2 (IC50:20 nM),FGFR1 (IC50:30 nM),PDGFRβ (IC50:510 nM)。 | |||
T2642 |
PD173074
|
Apoptosis; EGFR; VEGFR; FGFR; IGF-1R; Src | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD173074 是一种 FGFR1抑制剂,IC50为 25 nM。它也可抑制 VEGFR2活性,IC50值为 100-200 nM。 | |||
T16975 |
TAK-593
|
VEGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
TAK-593 是一种 VEGFR2 和 PDGFR 抑制剂,能够作用于VEGFR1 (IC50:3.2 nM)、VEGFR2 (IC50:0.95 nM)、VEGFR3 (IC50:1.1 nM)、PDFGRα (IC50:4.3 nM)、PDFGRβ (IC50:13 nM)。 | |||
T9724 |
VEGFR2-IN-2
|
Others | Others |
VEGFR2-IN-2 具有抗炎和镇痛活性。 | |||
T12598 |
Pz-1
|
VEGFR; c-RET | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Pz-1 是 VEGFR2 和 RET 酪氨酸激酶的抑制剂,可阻断 RET 刺激生长所需的血液供应。 | |||
T4425 |
JK-P3
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
JK-P3 是广谱 VEGFR2抑制剂。它能够抑制 VEGF-A 刺激的 VEGFR2 激活和细胞内信号转导,也可阻碍内皮单层细胞迁移和血管生成,影响成纤维细胞生长因子受体激酶在体外的活性。它具有抗血管生成的作用。 | |||
T5475 |
ZD-4190
|
EGFR; VEGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
ZD-4190 是血管内皮细胞生长因子受体 2 (VEGFR2) 和表皮生长因子受体 (EGFR) 信号传导的抑制剂,用于治疗癌症。 | |||
T2446 |
KI8751
|
EGFR; VEGFR; FGFR; PDGFR; c-Kit | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Ki8751 是一种有效的 VEGFR2 抑制剂,其 IC50=0.9 nM。 | |||
TQ0321 |
BIBF 1202
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BIBF 1202是 BIBF 1120的羧酸盐代谢物。BIBF 1202抑制 VEGFR2激酶的 IC50值为62 nM。 | |||
T7945 |
SU14813
|
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
SU14813 是一种多靶点受体酪氨酸激酶抑制剂,能够抑制 VEGFR2 (IC50:50 nM),VEGFR1 (IC50:2 nM),PDGFRβ (IC50:4 nM),KIT (IC50:15 nM)。 | |||
T9979 |
VEGFR-2-IN-29
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
VEGFR-2-IN-29是一种 VEGFR2抑制剂。 | |||
TQ0041 |
Ningetinib Tosylate
|
VEGFR; c-Met/HGFR; TAM Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
Ningetinib Tosylate 是口服具有活力的、小分子酪氨酸激酶抑制剂,能够抑制 c-Met (IC50:6.7 nM),VEGFR2 (IC50:1.9 nM) 和 Axl (IC50<1.0 nM)。 | |||
T9929 |
Ramucirumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ramucirumab 是一种人 VEGFR-2 拮抗剂,具有抗实体瘤活性。它是人源化单克隆抗体,能够与 VEGFR-2 结合,阻碍 VEGFR 配体 VEGF-A,VEGF-C 和 VEGF-D 结合。 | |||
T3566 |
SU5205
SU 5205 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SU5205 是一种 VEGFR2 (FLK-1) 的抑制剂,其IC50=9.6 μM。 | |||
T0097L |
Pazopanib
帕唑帕尼,GW786034 |
VEGFR; FGFR; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Pazopanib (GW786034) 是一种小分子抑制剂,可抑制多种具有潜在抗肿瘤活性的蛋白酪氨酸激酶。它抑制VEGFR1、VEGFR2、VEGFR3、PDGFRβ、c-Kit、FGFR1和c-Fms 的IC50分别为10、30、47、84、74、140和146 nM。 | |||
T1777 |
Nintedanib
BIBF 1120,Intedanib,尼达尼布 |
VEGFR; FGFR; FLT; PDGFR; Src | Angiogenesis; Tyrosine Kinase/Adaptors |
Nintedanib (Intedanib) 是一种三重血管激酶抑制剂,抑制 VEGFR1、VEGFR2、VEGFR3 (IC50=34/13/13 nM),FGFR1、FGFR2、FGFR3 (IC50=69/37/108 nM),PDGFRα、PDGFRβ (IC50=59/65 nM)。Nintedanib 具有抗肿瘤活性,通过抑制血管生成来抑制肿瘤生长。 | |||
T2419 |
BMS-794833
|
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BMS794833 是一种 VEGFR2 和 Met 的抑制剂,它们的 IC50值分别为 15 和 1.7 nM。 | |||
T6012 |
SAR131675
SAR 131675 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
SAR131675 是一种选择性的VEGFR3抑制剂,其IC50=23 nM。 | |||
T7611 |
ODM-203
|
VEGFR; FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
ODM-203 是 FGFR 和 VEGFR 家族的抑制剂,具有显著的抗肿瘤活性,能够诱导抗肿瘤免疫。 | |||
T15185 |
Lucitanib
E-3810,德立替尼 |
VEGFR; FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Lucitanib (E-3810) 是 VEGFR 和 FGFR 的双重抑制剂,有效和选择性地抑制VEGFR1 (IC50:7 nM),VEGFR2 (IC50:25 nM),VEGFR3 (IC50:10 nM),FGFR1 (IC50:17.5 nM),FGFR2 (IC50:82.5 nM)。 | |||
TQ0317 |
R1530
R-1530,R 1530 |
VEGFR; FGFR; FLT; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
R1530 是一种多激酶抑制剂,具有抗肿瘤和抗血管生成活性。它是具有口服活性的有丝分裂/血管生成高效双重作用抑制剂, 抑制 VGFR2、FGFR1作用的 IC50分别为 10 nM 和 28 nM。 | |||
T11520 |
GW806742X
|
MLK; VEGFR | Angiogenesis; MAPK; Tyrosine Kinase/Adaptors |
GW806742X 是ATP 模拟物,是MLKL 抑制剂,可结合 MLKL 假激酶结构域,Kd 值为 9.3μM。它对VEGFR2的IC50为 2 nM,延缓 MLKL 膜移位并抑制坏死。 | |||
T6166 |
Telatinib
Bay 57-9352,替拉替尼 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Telatinib (Bay 57-9352) 是一种口服具有活力的,小分子的 VEGFR2,VEGFR3,PDGFα 和 c-Kit 抑制剂,它们的 IC50 值分别为6,4,15,1 nM。 | |||
T2358 |
ENMD-2076
|
Apoptosis; VEGFR; FGFR; FLT; c-RET; PDGFR; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
ENMD2076是一种多靶点激酶抑制剂,抑制Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1、FGFR2、Src、PDGFRα的IC50值分别为1.86、14、58.2、15.9、92.7、70.8、20.2 and 56.4 nM。 | |||
T3476 |
JI-101
CGI-1842,JI 101 |
VEGFR; PDGFR; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
JI-101 (CGI-1842) 是一种有口服活性的多靶点激酶抑制剂,能够抑制VEGFR2,PDGFRβ和EphB4,具有抗癌作用。 | |||
T0520 |
Lenvatinib
仑伐替尼,E7080 |
VEGFR; FGFR; c-RET; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Lenvatinib (E7080) 是一种多靶点受体酪氨酸激酶抑制剂,抑制 VEGFR1-3、FGFR1-4、KIT、PDGFR 和 RET 等,具有口服活性。Lenvatinib 对 VEGFR2 和 VEGFR3 的抑制活性最强 (IC50=4/5.2 nM)。Lenvatinib 具有强效抗肿瘤活性。 | |||
T3570 |
SU4312
SU 4312,NSC 86429 |
VEGFR; PDGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
NSC-86429 是一种 (Z)-SU4312 (SU 4312) 和 (E)-SU4312 的外消旋体。其中(Z)-SU4312 能够抑制 PDGFR 和 FLK-1。(E)-SU4312 能够抑制 PDGFR, FLK-1, EGFR, HER-2, 和 IGF-1R。 | |||
T4288 |
hVEGF-IN-1
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
hVEGF-IN-1 是一种喹唑啉衍生物,可以特异性结合内部核糖体进入位点 A 中富含 G 的序列,并会使 G-四链体结构不稳定。在 SPR 实验中,它与 IRES-A (WT) 结合的Kd 值为 0.928 μM。它能够抑制VEGF-A 蛋白表达,阻止肿瘤细胞迁移,抑制肿瘤生长。 | |||
T1452 |
Axitinib
AG-013736,阿昔替尼,阿西替尼 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Axitinib (AG-013736) 是一种多靶点酪氨酸激酶抑制剂,能够抑制 VEGFR1 (IC50:4 nM),VEGFR2 (IC50:20 nM),VEGFR3 (IC50:0.4 nM),PDGFRβ (IC50:2 nM)。 | |||
T2064 |
Semaxinib
司马沙尼,SU5416 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1/KDR) 抑制剂,其 IC50=1.23 μM。 | |||
T4318 |
EOC317
ACTB-1003,ACTB1003,ACTB 1003 |
VEGFR; FGFR; Tie-2 | Angiogenesis; Tyrosine Kinase/Adaptors |
EOC317 (ACTB-1003) 是一种口服可用的激酶抑制剂,能够抑制 FGFR1 (IC50:6 nM),VEGFR2 (IC50:2 nM) 和 Tie-2 (IC50:4 nM)。 | |||
T2500 |
Cediranib
AZD2171,NSC-732208,西地尼布 |
VEGFR; FLT; PDGFR; c-Kit; Autophagy | Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors |
Cediranib (AZD2171) 是一种可口服的高选择性VEGFR2抑制剂,对Flt1、KDR、Flt4、PDGFRα、PDGFRβ和c-Kit 的IC50值分别为小于1、小于3、5、5、36和 2nM。 | |||
T1836 |
AZD2932
|
VEGFR; FLT; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
AZD2932是一种多靶点激酶抑制剂,细胞试验中能够抑制 VEGFR2 (IC50:8 nM),PDGFβ (IC50:4 nM),PDGFβ (IC50:7 nM) 和 PDGFβ (IC50:9 nM)。 | |||
T13178 |
Toceranib
托西尼布,PHA 291639E,SU11654 |
VEGFR; PDGFR; c-Kit | Angiogenesis; Tyrosine Kinase/Adaptors |
Toceranib (PHA 291639E) 是口服具有活力的受体酪氨酸激酶 (RTK) 抑制剂,能有效抑制PDGFR,VEGFR,Kit,抑制 PDGFRβ 和 Flk-1/KDR 的Ki 分别为 5 nM 和 6 nM。它具有抗肿瘤和抗血管生成作用,用于研究犬肥大细胞肿瘤。 | |||
T2638 |
Gandotinib
LY2784544 |
VEGFR; FGFR; FLT; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Gandotinib (LY2784544) 是一种JAK2抑制剂,IC50为 3 nM。它也抑制FLT3、FLT4、FGFR2、TYK2 和 TRKB,IC50分别为 4、25、32、44 和 95 nM。 | |||
T2656 |
Fruquintinib
HMPL-013,呋喹替尼 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Fruquintinib (HMPL-013) 是一种选择性的VEGFR 1/2/3抑制剂,它们的IC50值分别为33 nM、0.5 nM、35 nM。 | |||
T2372 |
Ponatinib
帕纳替尼,AP24534,普纳替尼 |
VEGFR; FGFR; Bcr-Abl; PDGFR; Src; c-Kit; Autophagy | Angiogenesis; Autophagy; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Ponatinib (AP24534) 是一种有多靶点激酶抑制剂,具有口服活性,可以抑制 Abl、PDGFRα、VEGFR2、FGFR1 和 Src (IC50=0.37/1.1/1.5/2.2/5.4 nM)。Ponatinib 具有抗肿瘤活性,可以用于治疗成人慢性粒细胞白血病。 | |||
T6036 |
Brivanib
BMS-540215,布立尼布 |
EGFR; VEGFR; FGFR; Autophagy | Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Brivanib (BMS-540215) 是一种针对 VEGFR2 的 ATP 竞争性抑制剂,IC50 为 25 nM。它对 VEGFR-1 和 FGFR-1 具有中等效力,对 VEGFR2 的选择性是对 PDGFR-β 的 240 倍。 | |||
T1656 |
Vandetanib
ZD6474,凡德他尼 |
Apoptosis; EGFR; VEGFR; Autophagy | Angiogenesis; Apoptosis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Vandetanib (ZD6474) 是一种具有口服活性的VEGFR2/KDR 酪氨酸激酶抑制剂,IC50值为40 nM。它也抑制VEGFR3/FLT4和EGFR/HER1,IC50值分别为110和500 nM。 | |||
T9928 |
Ranibizumab
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Ranibizumab 是一种人源化单克隆抗体片段,旨在靶向和抑制血管内皮生长因子 (VEGF),包括 VEGF110、VEGF121 和 VEGF165。 Ranibizumab 选择性靶向和中和 VEGF-A 同工型的能力使其成为湿性年龄相关性黄斑变性 (AMD) 研究和治疗策略的重要组成部分。 | |||
T1792L |
Regorafenib monohydrate
|
Raf; VEGFR; c-RET; PDGFR; c-Kit; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Regorafenib monohydrate 是一种新型口服多激酶抑制剂,对VEGFR1/2/3、PDGFRβ、Kit、RET 和Raf-1的IC50分别为 13、4.2、46、22、7、1.5 和 2.5 nM。 | |||
T3691 |
(Rac)-SAR131675
SAR131675 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
(Rac)-SAR131675 是一种有效的、选择性的VEGFR3抑制剂,其IC50=23 nM。 | |||
T3599 |
BFH772
BFH-722 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
BFH772 是 VEGFR2抑制剂(IC50:3 nM),具有口服活性。 | |||
T8402 |
Regorafenib Hydrochloride
瑞戈非尼盐酸盐,BAY73-4506 hydrochloride |
Raf; VEGFR; c-RET; PDGFR; Autophagy | Angiogenesis; Apoptosis; Autophagy; MAPK; Tyrosine Kinase/Adaptors |
Regorafenib Hydrochloride (BAY73-4506 hydrochloride) 是一种新型口服多激酶抑制剂,可抑制血管生成、基质和致癌受体酪氨酸激酶,具有强大的临床前抗肿瘤活性。它靶向作用于 VEGFR1/2/3、PDGFRβ、Kit、RET 和 Raf-1,IC50值分别为 13/4.2/46、22、7、1.5 和 2.5 nM。 | |||
T8541 |
Lenvatinib mesylate
仑伐替尼甲酸盐,E7080 (mesylate),乐伐替尼 |
VEGFR; FGFR; c-RET; PDGFR; c-Kit | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Lenvatinib mesylate (E7080 (mesylate)) 是一种口服具有活力的,多靶点酪氨酸激酶抑制剂,能够抑制血管内皮生长因子受体(VEGFR1-3),成纤维细胞生长因子受体(FGFR1-4),干细胞因子受体(KIT),血小板衍生生长因子受体(PDGFR),转染期间重排(RET),具有效抗癌作用。 | |||
T6184 |
Orantinib
SU6668,TSU-68,NSC 702827 |
Apoptosis; VEGFR; FGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Orantinib (NSC 702827) 是一种多靶点受体酪氨酸激酶抑制剂,对 Flt-1、PDGFRβ和FGFR1的Ki 值分别为 2.1 μM、8 nM 和 1.2 μM。 | |||
T7123 |
AMG-47a
|
VEGFR; p38 MAPK; JAK; Src | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Stem Cells; Tyrosine Kinase/Adaptors |
AMG-47a 是具有口服活性的 Lck 抑制剂,IC50值为 0.2 nM。它具有抗炎作用,对 VEGF2、p38α、p38α、Jak3、MLR 和 IL-2的 IC50值分别为 1、3、72、30 和 21 nM。 | |||
T6517 |
Golvatinib
E-7050,戈伐替尼 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。 | |||
TQ0059 |
Ilorasertib
ABT-348 |
VEGFR; FLT; c-RET; PDGFR; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Ilorasertib (ABT-348) 是一种 ATP 竞争性多靶点激酶抑制剂,可抑制 Aurora A、Aurora B 和Aurora C,IC50值为120 nM、7 nM 和1 nM。它还抑制 RET 酪氨酸激酶、PDGFRβ 和 Flt1,IC50为7 nM、3 nM 和 32 nM。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8213 |
Isolinderalactone
|
NOS; STAT | Immunology/Inflammation; JAK/STAT signaling; Stem Cells |
Isolinderalactone 具有抗炎和抗癌能力,具有中等的 iNOS 抑制活性,IC50 值为 0.30 uM。 | |||
T4A2456 |
Gamabufotalin
Gamabufagin,日本蟾蜍毒苷元 |
COX | Immunology/Inflammation; Neuroscience |
Gamabufotalin (Gamabufagin) 是一种蟾蜍甾烯,存在于蟾酥中。它稳定性高,毒性低,被广泛用于癌症的研究。 | |||
T17280 |
(Z)-Guggulsterone
|
Apoptosis; VEGFR; Akt | Angiogenesis; Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
(Z)-Guggulsterone 是印度阿育吠陀药用植物Commiphora mukul 的成分,可通过引起细胞凋亡来抑制人前列腺癌细胞的生长,还可通过抑制VEGF-VEGF-R2-Akt 信号传导轴来抑制血管生成。 | |||
T3S0153 |
Xanthatin
苍耳亭,叶黄制菌素 |
Apoptosis; VEGFR; Lipoxygenase; Wnt/beta-catenin; Antibacterial | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Metabolism; Microbiology/Virology; Stem Cells; Tyrosine Kinase/Adaptors |
Xanthatin 是一种从Xanthium strumarium 叶子中提取的天然产物,可诱导细胞凋亡。它抑制布鲁氏菌的IC50值为 2.63 μg/ mL,对寄生虫特异性锥虫硫磷还原酶具有不可逆的弱抑制作用。它通过抑制PGE2的合成和 5-脂氧合酶的活性而显示出抗炎活性。 | |||
T2906 |
Tanshinone IIA
丹参酮IIA,Tanshinone B,Dan Shen ketone |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Tanshinone IIA (Tanshinone B) 是红根丹参根系中的一种主要组合物。它能够利用靶向 VEGF/VEGFR2的蛋白激酶结构域,抑制血管生成。 | |||
T3673 |
Mollugin
大叶茜草素,Rubimaillin |
HER; JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
Mollugin (Rubimaillin) 是Rubia cordifolia L.中主要的生物活性成分。它能通过 p38-Smad 信号通路增强 BMP-2 的成骨作用。它通过抑制 TNF-α 诱导的 NF-κB 激活起抗癌疗效。 | |||
T7203 |
Oglufanide
奥谷法奈,L-Glutamyl-L-tryptophan,H-Glu-Trp-OH |
VEGFR; HCV Protease; Endogenous Metabolite | Angiogenesis; Metabolism; Microbiology/Virology; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
Oglufanide (H-Glu-Trp-OH) 是一种从小牛胸腺中分离出来的二肽免疫调节剂,可抑制血管内皮生长因子,可刺激细胞内细菌感染和对丙型肝炎病毒的免疫反应。 | |||
T1152 |
Albendazole
SKF-62979,阿苯达唑 |
HIF/HIF Prolyl-Hydroxylase; Microtubule Associated; Antibiotic; Parasite | Chromatin/Epigenetic; Cytoskeletal Signaling; Metabolism; Microbiology/Virology |
Albendazole (SKF-62979) 是一种广谱抗寄生虫剂,具有高效,低宿主毒性的特点。 它用于研究人类和动物的胃肠道寄生虫。 | |||
TN2019 |
Orobol
3'-Hydroxygenistein,3’,4’,5,7-tetrahydroxy-isoflavon,3',4',5,7-四羟基异黄酮 |
BCL; Caspase; PI3K | Apoptosis; PI3K/Akt/mTOR signaling; Proteases/Proteasome |
Orobol (3’,4’,5,7-tetrahydroxy-isoflavon) 是酪氨酸特异性蛋白激酶和磷脂酰肌醇转换的抑制剂。Orobol 抑制 PI3K,对 PI3K α/β/γ/K/δ 的 IC50 为 3.46-5.27 μM。 Orobol 具有抗皮肤老化和抗肥胖的作用。 | |||
T13108 |
Pamufetinib
H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115 |
VEGFR; c-Met/HGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Pamufetinib (TAS-115) 是VEGFR 和c-Met/HGFR 抑制剂,能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。 | |||
T1205 |
Chloramphenicol
Chlornitromycin,Levomycetin,Chloromycetin,氯霉素 |
ribosome; HIF/HIF Prolyl-Hydroxylase; Antibacterial; Antibiotic | Chromatin/Epigenetic; Metabolism; Microbiology/Virology |
Chloramphenicol (Chloromycetin) 是一种广谱抗生素,有效抑制细菌蛋白质生物合成。它主要作用于细菌 70S 核糖体的 50S 亚基,对肽基转移酶有活性,抑制肽键的形成。 | |||
TWA2417 |
Sodium taurocholate
牛黄胆酸钠(牛胆酸钠,牛胆酸钠盐,牛磺膽酸鈉,牛磺胆酸钠,牛磺胆酸钠盐,牛胆酸钠水合物,水合牛磺胆酸钠,牛胆酸钠(混合物),牛黄胆酸钠(水合),牛磺胆酸钠(标准品)),Taurocholate Sodium |
Others | Others |
Sodium taurocholate (Taurocholate Sodium) hydrate 具有显著的生物学效应,例如通过上调 VEGF-A 的表达抑制肝动脉结扎所致的胆道损伤。对免疫系统具有一定的调节作用。 | |||
T14055 |
5Z-7-Oxozeaenol
FR148083,L783279,LL-Z 1640-2 |
VEGFR; FLT; MEK; MAPK; PDGFR; Antibiotic; Src | Angiogenesis; MAPK; Microbiology/Virology; Tyrosine Kinase/Adaptors |
5Z-7-Oxozeaenol (FR148083) 是一种天然抗原生动物抑制剂,不可逆的选择性抑制 TAK1和 VEGF-R2,IC50值分别为 8 nM 和 52 nM。 | |||
T7044 |
Norepinephrine
去甲肾上腺素,Levophed,Levonoradrenaline,Aktamin,Nor-Epirenan,Levonor,Arterenol |
MMP; Endogenous Metabolite; Adrenergic Receptor; Autophagy | Autophagy; GPCR/G Protein; Metabolism; Neuroscience; Proteases/Proteasome |
Norepinephrine (Levophed) 属于生物碱类天然产物,是一种神经递质,一种肾上腺素能受体 (AR) 的激动剂,对 α1、α2 和 β1 AR 具有激活活性。Norepinephrine 被用作抗休克的血管活性剂。 | |||
T38250 |
L-Sepiapterin
|
Others | Others |
L-Sepiapterin, also known as Sepiapterin, is a precursor compound crucial for the production of tetrahydrobiopterin (BH4), which serves as a coenzyme for endothelial nitric oxide synthase (eNOS). This compound demonstrates its efficacy by improving endothelial dysfunction in small mesenteric arteries from db/db mice and promoting angiogenesis. Moreover, L-Sepiapterin exerts inhibitory effects on cellular proliferation and migration in ovarian cancer cells through the down-regulation of p70S6K-de... | |||
TN5050 |
Sprengerinin C
|
NADPH-oxidase; VEGFR; p38 MAPK; ROS; Akt; PI3K; mTOR; p53 | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Immunology/Inflammation; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tumor angiogenesis in human umbilical vein endothelial cells, it blocks vascul |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00412 |
VEGFR1/FLT-1 Protein, Human, Recombinant (hFc)
Vascular endothelial growth f... |
Human | HEK293 Cells |
Human Vascular endothelial growth factor receptor 1(VEGFR-1, FLT-1) is a member of the the class III subfamily of receptor tyrosine kinases (RTKs) and Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR-1 is widely expressed in human tissues including normal lung, placenta, liver, kidney, heart and brain tissues. It is specifically expressed in most of the vascular endothelial cellsand peripheral blood monocytes. VEGFR-1 contains seven Ig-like C2-type domains and one protein kinas... | |||
TMPJ-00414 |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated
Protein-tyrosine kinase receptor flk-1,KDR,Kinase i... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 120-150 KDa and the accession number is P35968. | |||
TMPJ-00593 |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His)
KDR,Fetal liver kinase 1,VEGFR-2,Kinase insert domain re... |
Human | HEK293 Cells |
VEGFR2/KDR Protein, Human, Recombinant (aa 20-764, His) is expressed in HEK293 mammalian cells with C-6xHis tag. The predicted molecular weight is 110-140 KDa and the accession number is AAI31823.1. | |||
TMPK-00978 |
ECSCR Protein, Human, Recombinant (hFc)
ECSM2,ECSCR,ARIA |
Human | HEK293 Cells |
Endothelial cell-specific chemotaxis receptor (ECSCR) is a cell surface protein expressed by blood endothelial cells with roles in endothelial cell migration and signal transduction. Zebrafish ecscr is expressed in angioblasts and in axial vessels during angioblast migration and vasculogenesis. Morpholino-directed ecscr knockdown resulted in defective angioblast migration in the posterior lateral plate mesoderm, a process known to depend on vascular endothelial-derived growth factor (VEGF). ECSC... | |||
TMPK-00988 |
ECSCR Protein, Mouse, Recombinant (hFc)
ECSCR,ARIA,ECSM2 |
Mouse | HEK293 Cells |
Endothelial cell-specific chemotaxis receptor (ECSCR) is a cell surface protein expressed by blood endothelial cells with roles in endothelial cell migration and signal transduction. Zebrafish ecscr is expressed in angioblasts and in axial vessels during angioblast migration and vasculogenesis. Morpholino-directed ecscr knockdown resulted in defective angioblast migration in the posterior lateral plate mesoderm, a process known to depend on vascular endothelial-derived growth factor (VEGF). ECSC... | |||
TMPK-00645 |
VEGFR2/KDR Protein, Rhesus macaque, Recombinant (His)
KRD1,VEGFR2,FLK1,CD309,Ly73,VEGFR,VEGFR-21,KDR |
Rhesus | HEK293 Cells |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. VEGFR2/KDR Protein, Rhesus macaque, Recombinant (His) is expressed in HEK293 mammalian cells with ... | |||
TMPK-00454 |
VEGFR2/KDR Protein, Human, Recombinant (His & Avi)
VEGFR-21,Ly73,KRD1,VEGFR2,CD309,FLK1,VEGFR,KDR |
Human | HEK293 Cells |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. The tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) is a key regulator of angiogenesis. VEGFR2/KDR Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-H... | |||
TMPY-01709 |
HIF-1 alpha Protein, Human, Recombinant (His)
bHLHe78,HIF-1 α,hypoxia inducible factor 1, alpha s... |
Human | E. coli |
HIF-1 alpha, also known as HIF1A, contains 1 basic helix-loop-helix (bHLH) domain, 1 PAC (PAS-associated C-terminal) domain, and 2 PAS (PER-ARNT-SIM) domains. It is one of the two subunits of Hypoxia-inducible factor-1 (HIF1). HIF1 is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of an alpha subunit and a beta subunit. The beta subunit has... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TMIH-0124 |
Brivanib Alaninate-d4
|
||
Brivanib Alaninate-d4 是 Brivanib Alaninate 的氘代化合物。Brivanib Alaninate 的 CAS 号为 649735-63-7。Brivanib alaninate 是一种血管内皮生长因子受体 2 (VEGFR2) 抑制剂的丙氨酸盐,IC50值为 25 nM,具有潜在的抗肿瘤活性。它对 VEGFR1 和 FGFR1 适度抑制,对 VEGFR2 的选择性是对 PDGFRβ 的 240 倍。 |